AbbVie seeks lift from 'guided missile' cancer drug with $10 billion ImmunoGen deal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street lower on AI spending jitters; oil prices rebound
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| AbbVie (NYSE: ABBV) | Delayed: 283.57 -1.23 (0.43%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $284.80 | 52 Week High | $68.12 | |||
| Open | $284.57 | 52 Week Low | $50.71 | |||
| Day High | $285.36 | P/E | 61.51 | |||
| Day Low | $278.01 | EPS | $4.61 | |||
| Volume | 2,157,059 | |||||
| Immunogen, Inc. (NASDAQ: IMGN) | Delayed: 31.25 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $31.25 | 52 Week High | $14.22 | |||
| Open | $240.83 | 52 Week Low | $1.51 | |||
| Day High | $31.25 | P/E | N/A | |||
| Day Low | $31.25 | EPS | $-0.36 | |||
| Volume | 670,938 | |||||
